NASDAQ: DMTKDermtech Inc Stock
$0.62+0.02 (+3.33%)
Updated Apr 23, 2024
DMTK Price
$0.62
Fair Value Price
N/A
Market Cap
$21.33M
52 Week Low
$0.58
52 Week High
$3.93
P/E
-0.2x
P/B
0.37x
P/S
3.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.30M
Earnings
-$100.89M
Gross Margin
1.8%
Operating Margin
-659.57%
Profit Margin
-659.6%
Debt to Equity
1.13
Operating Cash Flow
-$77M
Beta
1.23
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DMTK Overview
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DMTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMTK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DMTK is good value based on its book value relative to its share price (0.37x), compared to the US Diagnostics & Research industry average (4.24x)
P/B vs Industry Valuation
DMTK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DMTK due diligence checks available for Premium users.
Be the first to know about important DMTK news, forecast changes, insider trades & much more!
DMTK News
Valuation
DMTK fair value
Fair Value of DMTK stock based on Discounted Cash Flow (DCF)
Price
$0.62
Fair Value
$2.85
Undervalued by
78.21%
DMTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DMTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
38.97x
Market
41.92x
DMTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
4.24x
DMTK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMTK's financial health
Profit margin
Revenue
$3.9M
Net Income
-$19.1M
Profit Margin
-486.5%
DMTK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DMTK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$121.9M
Liabilities
$64.8M
Debt to equity
1.13
DMTK's short-term assets ($61.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMTK's short-term assets ($61.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMTK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.7M
Investing
$12.2M
Financing
-$24.0k
DMTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMTK vs Diagnostic & Research Stocks
Dermtech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.